Cancer Genetics (CGIX) Raised to Sell at ValuEngine

ValuEngine upgraded shares of Cancer Genetics (NASDAQ:CGIX) from a strong sell rating to a sell rating in a research report released on Friday morning.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Cancer Genetics from a sell rating to a hold rating in a report on Wednesday, November 29th. HC Wainwright set a $6.00 target price on shares of Cancer Genetics and gave the stock a buy rating in a report on Wednesday, November 29th. Finally, Maxim Group assumed coverage on shares of Cancer Genetics in a report on Thursday, December 7th. They issued a buy rating and a $6.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Cancer Genetics presently has a consensus rating of Hold and an average price target of $5.56.

Shares of Cancer Genetics (NASDAQ CGIX) opened at $1.90 on Friday. Cancer Genetics has a 1 year low of $1.70 and a 1 year high of $5.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01. The stock has a market cap of $49.18, a price-to-earnings ratio of -2.32 and a beta of 1.14.

Cancer Genetics (NASDAQ:CGIX) last issued its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). Cancer Genetics had a negative net margin of 54.65% and a negative return on equity of 46.21%. sell-side analysts forecast that Cancer Genetics will post -0.82 earnings per share for the current year.

In other news, Director John Pappajohn bought 150,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The stock was bought at an average price of $1.86 per share, with a total value of $279,000.00. Following the acquisition, the director now owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 21.30% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Perkins Capital Management Inc. boosted its holdings in Cancer Genetics by 22.7% in the 4th quarter. Perkins Capital Management Inc. now owns 989,700 shares of the medical research company’s stock worth $1,831,000 after buying an additional 183,000 shares during the period. Granahan Investment Management Inc. MA boosted its holdings in Cancer Genetics by 26.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after buying an additional 49,371 shares during the period. Vanguard Group Inc. boosted its holdings in Cancer Genetics by 61.9% in the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after buying an additional 197,619 shares during the period. Finally, Northern Trust Corp boosted its holdings in Cancer Genetics by 61.0% in the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after buying an additional 12,168 shares during the period. 11.74% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Cancer Genetics (CGIX) Raised to Sell at ValuEngine” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/06/cancer-genetics-cgix-raised-to-sell-at-valuengine.html.

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply